ClinicalTrials.gg

Program

TQB3201

A development code. Also written as “TQB3201 tablets”.

In Sino Biopharmaceutical's pipeline, AR PROTAC. Its studies are mostly in Prostatic Neoplasms, led by Sino Biopharmaceutical.

Furthest: phase 2, since Sep 8, 20251 company-led study, 1 open or runningNext primary completion: Apr 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Sino Biopharmaceutical11 open or runningphase 2since Sep 8, 2025Sep 8, 2025Apr 2027phase 2 · NCT07172126
  • Named in Sino Biopharmaceutical’s own pipeline as TQB3201, phase 1, as of Nov 16, 2026 (source).

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Sep 8, 2025First study: phase 2 study in Metastatic Castration-resistant Prostate CancerFirst studyNCT07172126 · 291 planned · China

Ahead

  1. Apr 2027Primary completion: phase 2 study in Metastatic Castration-resistant Prostate CancerNCT07172126

TargetBeta

“AR PROTAC”the company's pipeline, read by Claude · source

Other programs on AR

ProgramCompanyFurthest phaseStudies
enzalutamideruleAstellas Pharmaphase 469
apalutamideruleJohnson & Johnsonphase 431
darolutamideruleBayerphase 426
Clascoteronerulecassiopea-spaphase 419
ostarinerulegtxphase 315
rezvilutamideruleJiangsu HengRui Medicinephase 313
dezandrodegruleBristol-Myers Squibbphase 35
Cyproterone AcetateruleEurofarma Laboratoriosphase 34
Androgen Receptor-targeting Regulated Induced Proximity Targeting Chimera HLD-0915Johnson & Johnsonphase 33
HRS-5041Jiangsu HengRui Medicinephase 26
luxdegalutamideNovartisphase 23
luxdegalutamideNovartisphase 22

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07172126Metastatic Castration-resistant Prostate Cancer · China2Not yet recruitingApr 2027291

How it is read

Names in the registry

  • “TQB3201 tablets”, 1 entry

Codes read as this program: TQB3201.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.